While most Australians watch their share portfolios swing and property returns grow increasingly uncertain, registered pharmacists have access to something the rest of the market simply cannot touch.
Australian equity markets have had a difficult year. The ASX 200 recorded its worst weekly performance since June 2022 as geopolitical tensions in the Middle East escalated, energy prices surged, and speculation over the path of domestic interest rates intensified. Consumer confidence fell to a record low in the wake of the Iran conflict before edging up only slightly. Small business confidence, according to the NAB quarterly survey, has fallen to a 15-month low. GDP growth has eased sharply, constrained by cost-of-living pressures and tighter financial conditions.
For most investors, this is an uncomfortable place to be. For registered pharmacists, it is a timely reminder of just how unusual and valuable their position is. Under Australian law, only registered pharmacists can own a community pharmacy. That single regulatory fact places pharmacy ownership in a category that is simply not available to the general public, no matter how much capital they have or how eagerly they might seek it out.
In a world of volatile markets and uncertain returns, that exclusivity is worth pausing to appreciate.
An Essential Service in an Uncertain Economy
Community pharmacy is one of the very few small business categories formally designated as an essential service. Australians do not stop filling prescriptions when petrol prices rise, share markets fall, or consumer confidence weakens. The medications people need to manage chronic conditions, acute illness, and ongoing health needs are not discretionary purchases that get cut from the household budget in hard times.
That essential services status was put to its most demanding test during the COVID-19 pandemic, when large parts of the Australian economy were forced to close. Pharmacies remained open throughout, continuing to serve their communities while restaurants, retailers, and countless other small businesses faced existential uncertainty. The Pharmacy Guild of Australia formally confirmed this designation, and the sector emerged from the pandemic widely recognised as a stable and dependable pillar of the national healthcare system.
Compare that with the experience of most small business owners in 2026. KPMG’s Q2 2026 Economic Outlook notes that business conditions and productivity remain weak, with growth expected to stay subdued throughout the year. The hospitality sector continues to battle cost pressures and softening discretionary spending. Retail faces the dual challenge of cautious consumers and rising operating costs. For pharmacists, the structural picture looks markedly different.
Demographic Tailwinds That No Recession Can Reverse
Underpinning the resilience of community pharmacy is a demographic reality that is entirely independent of economic cycles. Australia’s population is ageing, and older Australians are the heaviest users of pharmacy services by a significant margin.
Research published by the University of Western Australia in September 2025, drawing on a decade of PBS data, found that the number of older Australians dispensed at least one PBS medicine in a calendar year grew by 40 per cent between 2013 and 2023, rising from 3.16 million to 4.42 million people. Over the same period, the number of older Australians regularly using five or more PBS medications increased by 32 per cent. In 2023, Australians aged over 65 had an average of 31 PBS-subsidised medicines dispensed throughout the year.
Australia’s over-65 cohort now exceeds 4.2 million people and is projected to continue growing substantially over coming decades. That is not a market trend that reverses when interest rates rise or geopolitical tensions flare. It is a structural, long-term driver of demand that sits beneath the day-to-day noise of economic conditions and keeps community pharmacy busy regardless of what the broader economy is doing.
A Revenue Floor That Most Small Businesses Can Only Envy
Perhaps the most distinctive financial characteristic of community pharmacy, and the one that most clearly sets it apart from virtually every other small business investment, is the government funding framework that underpins its core revenue.
The 8th Community Pharmacy Agreement, which commenced on 1 July 2024, delivers a total funding envelope of 6.5 billion over five years. Of that, 2.5 billion is allocated specifically to community pharmacies for dispensing prescriptions. Critically, PBS remuneration per script is now set to increase year-on-year across the life of the agreement, indexed to CPI. That is a structural protection against inflation that the owner of a cafe, a clothing boutique, or a trade business simply does not have.
To put that in context: most small business owners spend considerable energy each year worrying about whether their revenue will hold up. Community pharmacists operate within a framework where a substantial portion of their income is contractually committed by the federal government five years at a time. In the current economic environment, that kind of certainty is genuinely rare.
A Profession Expanding Its Reach
Beyond the dispensing core, the role of community pharmacy in the Australian healthcare system is actively expanding. The 2025 UTS Community Pharmacy Barometer, Australia’s only measure of pharmacist confidence, recorded its highest confidence score in the survey’s history, with expanded scope of practice identified as the key driver of renewed optimism.
Vaccinations, chronic disease management, minor ailment treatment, and medication reviews are all areas where pharmacists are taking on a broader clinical role, diversifying the revenue base of community pharmacies beyond their traditional dispensing function. The 8CPA itself includes a 30 per cent increase in funding for Community Pharmacy Programs, supporting this expanded scope of service delivery.
For pharmacist-owners, that expanding scope means the investment case for community pharmacy is not static. The business they are buying today has a broader revenue potential than the one their predecessors purchased a decade ago, and the trajectory points toward further expansion rather than contraction.
What the Market Is Telling Us
The pharmacy sales market has absorbed considerable headwinds in recent years. The federal government’s 60-day dispensing reforms, which took effect from September 2023, created short-term uncertainty around forward earnings for many pharmacies. A sustained period of interest rate rises dampened buyer confidence through FY2024. And yet, by FY2026, the market has rebounded strongly, with buyer demand for quality pharmacies remaining robust despite the RBA having raised the cash rate three times in 2026 alone.
That resilience is not accidental. It reflects the considered judgement of pharmacist-buyers who understand exactly what they are acquiring: a government-backed, demographically driven, essential services business in an asset class that is, by law, theirs alone.
The Privilege of Access
There are no shortage of Australians who would welcome the opportunity to invest in a business with government-backed revenue, demographic tailwinds, essential service status, and a structurally expanding role in the national healthcare system. The regulatory framework means they cannot. That privilege belongs exclusively to registered pharmacists.
In a year when share markets have been rattled by geopolitical shocks, property faces affordability constraints and rising holding costs, and small business confidence is fragile, that exclusivity deserves to be recognised for what it is: a genuinely rare and structurally sound investment opportunity, available only to those who have earned the right to hold it.
Sources: KPMG Australia Economic Outlook Q2 2026; University of Western Australia / The Conversation, September 2025; UTS Community Pharmacy Barometer 2025; Pharmacy Guild of Australia; Office of Impact Analysis, Australian Government; ASX market data.
Written by David Gilbert, SA & NT State Manager – AP Group
AP Group are the leading pharmacy experts in Australia, helping hundreds of pharmacists into ownership every year – our team can help with sourcing finance for your purchase, as well as providing the right legal advice to help you navigate the process.
We connect existing pharmacy owners with over 5000 ready and eager investors via our cutting-edge online Data Room. Our Data Room keeps confidential listing data secure and allows buyers to make informed decisions on each of our pharmacies for sale.
About the Author:
An infectious personality, family man and golf enthusiast. David is the kind of guy you’ll meet in person and leave feeling more energised than when you arrived. If he could play golf twice a day, every day, he would. But for now, he fits golf around his four kids and genuine love for helping pharmacists reach their goals. Busy guy.
Before entering the retail pharmacy industry, David owned and operated the Austral Hotel in Adelaide for 12 years. His personable nature, charisma and passion for hospitality saw him grow the business to an iconic hotel recognised by almost every South Australian (and beyond).
When it was time for a career change, David embraced the opportunity to enter the pharmacy space, bringing his hardworking and adaptable nature to the role. When asked what he loves about the role, it’s hands down the people, relationships, travel and using different parts of his brain.